Whitmore W F
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Cancer. 1993 Feb 1;71(3 Suppl):970-5. doi: 10.1002/1097-0142(19930201)71:3+<970::aid-cncr2820711412>3.0.co;2-6.
The management of early stage prostatic cancer is controversial.
Pertinent literature concerning the conservative management of early stage prostatic cancer by early endocrine therapy (EET) or by deferred treatment (DT) was reviewed.
EET has not been systematically studied. Available evidence suggests that early stage prostatic cancer often progresses slowly and that DT results in a cancer-specific mortality of approximately 80% at 10 years.
EET warrants clinical investigation. DT is a management option, at least in patients with a life expectancy of 10 years or less.
早期前列腺癌的治疗存在争议。
回顾了有关早期内分泌治疗（EET）或延迟治疗（DT）对早期前列腺癌进行保守治疗的相关文献。
EET尚未得到系统研究。现有证据表明，早期前列腺癌通常进展缓慢，DT导致10年时的癌症特异性死亡率约为80%。
EET值得进行临床研究。DT是一种治疗选择，至少对于预期寿命为10年或更短的患者是如此。
